12. EchoStar Corporation (NASDAQ:SATS)
EchoStar Corporation (NASDAQ:SATS) ranks among the best growth stocks to buy and hold for the long term. On March 2, EchoStar Corporation (NASDAQ:SATS) released its fourth-quarter 2025 earnings results, which highlighted the company’s capacity to boost profitability in spite of revenue challenges and subscriber pressure.
Compared to the previous quarter’s $231 million and 6.4% margin, the company’s adjusted OIBDA increased significantly to $584 million with a 15.4% margin. This feat was largely driven by careful cost management, with the cost of services falling 13.9% year-over-year to $2,181 million.
That said, EchoStar’s wireless division posted a mixed performance in the quarter. Following three straight quarters of subscriber gains totaling 585,000 net additions, the segment saw a net loss of 9,000 in Q4 2025.
In addition, the company scrapped its direct-to-device satellite constellation program in favor of a strategic alliance with SpaceX/Starlink. During the earnings call, Executive Chairman Charlie Ergen described SpaceX as “the best company I’ve ever worked with in 45 years.”
EchoStar Corporation (NASDAQ:SATS) is a global communications and content delivery company. It specializes in providing satellite communication, wireless telecommunications, internet services, as well as television and mobile services.
11. Argenx SE (NASDAQ:ARGX)
Argenx SE (NASDAQ:ARGX) ranks among the best growth stocks to buy and hold for the long term. Following the company’s Q4 results, Oppenheimer increased its price target for Argenx SE (NASDAQ:ARGX) to $1,060 from $1,040 on February 26 while keeping an Outperform rating.
The company reported earnings per share of $8.02, exceeding the projected $5.95. Revenue also came in slightly above expectations, totaling $1.29 billion vs $1.28 billion.
According to Oppenheimer, Vyvgart’s total revenues for the fourth quarter of 2025 totaled $1.29 billion, a 74% increase over the previous year. Vyvgart’s crucial myositis readout in the third quarter may pave the path for an additional 20,000-patient opportunity.
Additionally, on February 26, BofA Securities maintained a Buy rating on Argenx SE (NASDAQ:ARGX) and increased its price objective from $1,006 to $1,013. The firm ranked Argenx as a top pick and kept its Vyvgart sales projection flat compared to the fourth quarter of 2025 for the coming first-quarter 2026 earnings.
Argenx SE (NASDAQ:ARGX) is a Netherlands-based global biotechnology company focused on developing, manufacturing, and commercializing antibody-based therapies for severe autoimmune diseases and cancers.
